Discover Leishmaniasis (Kala-Azar) Therapeutic Pipeline H2 2016, Drug Profile and Major Key Players

Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.


Pune, Maharashtra -- (SBWire) -- 01/31/2017 --Leishmaniasis (Kala-Azar) Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Leishmaniasis (Kala-Azar) therapeutics industry report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Browse more detail information about Leishmaniasis (Kala-Azar) market report at:

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016:
- Advinus Therapeutics Ltd
- BioLingus AG
- iCo Therapeutics Inc.
- Laboratorios LETI S.L.
- ManRos Therapeutics
- Matinas BioPharma Holdings, Inc.
- Nanomerics Ltd
- Novartis AG
- Oblita Therapeutics BVBA

Get a PDF Sample of Leishmaniasis (Kala-Azar)Market Research Report at:

Key Topics Covered:
2.Leishmaniasis (Kala-Azar) Overview
3.Leishmaniasis (Kala-Azar) Therapeutics Development
4.Pipeline Products for Leishmaniasis (Kala-Azar) - Overview
5.Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis
6.Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies
7.Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes
8.Leishmaniasis (Kala-Azar) Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Leishmaniasis (Kala-Azar) - Products under Development by Companies
13.Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes
14.Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
15.Leishmaniasis (Kala-Azar) Drug Profiles
16.Leishmaniasis (Kala-Azar) Dormant Projects
17.Leishmaniasis (Kala-Azar) Discontinued Products
18.Leishmaniasis (Kala-Azar) Featured News & Press Releases
Dec 15, 2015: U.S. Issues Patent on Corifungin 93
Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
Feb 26, 2013: National Institutes of Health Supports Acea's Research
Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS
Jul 01, 2011: FDA issues orphan-drug designation to Corifungin
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis

And Continue…

Get Discount on Leishmaniasis (Kala-Azar)Market Research Report at:

List of Figures
- Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016
- Number of Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Number of Products by Top 10 Targets, H2 2016
- Number of Products by Stage and Top 10 Targets, H2 2016
- Number of Products by Top 10 Mechanism of Actions, H2 2016
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016

About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Media Relations Contact

Ameya Pingaley
Absolute Reports

View this press release online at: